Table 1.

Currently active and ongoing clinical trials targeting the CD155/TIGIT axis

Immunotherapy type	Immunotherapy targets	Disease	Treatment	Phase	Clinical trial identifier	Sponsor
Checkpoint inhibitor	CD155 (PVR), PD-1	Solid tumors	COM701, Opdivo (nivolumab)	1	NCT03667716	Compugen Ltd, Bristol-Myers Squibb
Oncolytic virus	CD155 (PVR)	Melanoma	PVSRIPO	1	NCT03712358	Istari Oncology, Inc., Duke University
Oncolytic virus	CD155 (PVR)	Glioblastoma, malignant glioma	PVSRIPO	1	NCT01491893	Istari Oncology, Inc., National Cancer Institute (NCI), Brain Tumor Research Charity Grant, Duke University
Monoclonal antibody	TIGIT, PD-1	Metastatic solid tumors	BGB-A1217, tislelizumab	1	NCT04047862	BeiGene
Monoclonal antibody	TIGIT, PD-L1	Non-small cell lung cancer	Atezolizumab, MTIG7192A	2	NCT03563716	Genentech, Inc.
Monoclonal antibody	TIGIT, PD-L1	Small cell lung cancer	Tiragolumab atezolizumab, carboplatin, etoposide	3	NCT04256421	Hoffmann-La Roche
Monoclonal antibody	TIGIT, PD-L1	Non-small cell lung cancer	Atezolizumab, tiragolumab	3	NCT04294810	Hoffmann-La Roche
Monoclonal antibody	TIGIT, PD-1	Solid tumors	AB154, AB122	1	NCT03628677	Arcus Biosciences, Inc.
Monoclonal antibody	TIGIT, PD-1, A2aR/A2bR	Non-small cell lung cancer	Zimberelimab, AB154, AB928	2	NCT04262856	Arcus Biosciences, Inc.
Monoclonal antibody	TIGIT, D-L1, MEK1/2, VEGFR2, CXCR4, DPP-4	Gastric adenocarcinoma, esophageal carcinoma	5-Fluorouracil (5-FU), leucovorin, oxaliplatin, atezolizumab, cobimetinib, ramucirumab, paclitaxel, PEGPH20, BL-8040, linagliptin, cisplatin, tiragolumab	1/2	NCT03281369	Hoffmann-La Roche, Halozyme Therapeutics, BioLineRx, Ltd.